TRVI vs DBVT vs IQV vs ALKS

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Trevi Therapeutics, Inc. (TRVI) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus Alkermes plc at 24. 8x.

Over the past 5 years, Trevi Therapeutics, Inc.

(TRVI) delivered a total return of +569. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: IQV returned +166. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 26% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Trevi Therapeutics, Inc. (TRVI) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Trevi Therapeutics, Inc. grew EPS 38. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Trevi Therapeutics, Inc.

(TRVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 06)). Both have compounded well over 10 years (TRVI: +78. 1%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.